KDA GROUP ANNOUNCES PARTNERSHIP AGREEMENT WITH CHU DE QUEBEC-UNIVERSITE LAVAL FOR THE DEPLOYMENT OF MEDHERIZE

Executive Summary

• KDA Group Inc. signed a partnership and collaboration agreement with the Centre hospitalier universitaire de Québec, Université Laval (CHU de Québec) to deploy its Medherize platform at Hôpital du Saint‑Sacrement.
• The agreement aims to expand Medherize from breast‑cancer oral therapy monitoring to additional oncology, autoimmune and rare‑disease treatments across Quebec, Canada and eventually internationally.
• The partnership is expected to generate significant commercial interest from pharmaceutical companies, pharmacy chains and independent pharmacists, creating new revenue opportunities for KDA’s SaaS solution.

Key Details

• Partnership Scope: Deployment of Medherize at Hôpital du Saint‑Sacrement with plans to roll out to other CHU de Québec hospitals and later to additional Canadian and international sites.
• Target Indications: Initially breast‑cancer oral therapies; future expansion to biotherapies, broader oncology agents, autoimmune diseases and rare genetic disorders.
• Platform Capabilities: Real‑time therapeutic monitoring, integration with Dossier Santé Québec (DSQ), automated adverse‑effect management, shared patient treatment view for care teams.
• Commercial Impact: Early interest from multiple pharmaceutical firms, pharmacy chains and independent pharmacists; potential to broaden KDA’s customer base and increase SaaS subscription revenue.
• Leadership Quotes:
• Marc Lemieux (CEO & Chairman, KDA) – highlighted Medherize’s role in optimizing personalized treatment and improving patient quality of life.
• Dr. Julien Clément (Director, Professional Services & Medical Affairs, CHU de Québec) – noted time‑saving benefits for healthcare professionals and resource optimization.
• Patient Testimonial: Ms. M. McNeil Caron, a Medherize user, praised the platform’s ease of use and confidence it provides in treatment follow‑up.
• Future Outlook: KDA expects the partnership to serve as a springboard for broader adoption across Canada and internationally, supporting its growth strategy in the specialty‑medication management market.

Notable Quotes

“Our Medherize solution is designed to support healthcare professionals in delivering optimized and personalized treatments while enhancing patients' quality of life.” – Marc Lemieux, CEO & Chairman, KDA Group

“The implementation of Medherize within our institution could potentially allow our healthcare professionals to save time in treatment follow‑up and optimize the use of our resources, to the direct benefit of our patients.” – Dr. Julien Clément, Director of Professional Services and Medical Affairs, CHU de Québec